342 related articles for article (PubMed ID: 22077832)
1. Telmisartan: just an antihypertensive agent? A literature review.
Destro M; Cagnoni F; Dognini GP; Galimberti V; Taietti C; Cavalleri C; Galli E
Expert Opin Pharmacother; 2011 Dec; 12(17):2719-35. PubMed ID: 22077832
[TBL] [Abstract][Full Text] [Related]
2. New standards in hypertension and cardiovascular risk management: focus on telmisartan.
Galzerano D; Capogrosso C; Di Michele S; Galzerano A; Paparello P; Lama D; Gaudio C
Vasc Health Risk Manag; 2010 Mar; 6():113-33. PubMed ID: 20448797
[TBL] [Abstract][Full Text] [Related]
3. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Yamagishi S; Takeuchi M
Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
[TBL] [Abstract][Full Text] [Related]
4. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation.
Yamagishi S; Takenaka K; Inoue H
Med Hypotheses; 2006; 66(1):118-20. PubMed ID: 16154710
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes.
Cao Z; Cooper ME
Acta Diabetol; 2012 Aug; 49(4):243-54. PubMed ID: 21947383
[TBL] [Abstract][Full Text] [Related]
6. Clinical effectiveness of telmisartan alone or in combination therapy for controlling blood pressure and vascular risk in the elderly.
Jugdutt BI
Clin Interv Aging; 2010 Dec; 5():403-16. PubMed ID: 21152242
[TBL] [Abstract][Full Text] [Related]
7. Telmisartan: a different angiotensin II receptor blocker protecting a different population?
Burnier M
J Int Med Res; 2009; 37(6):1662-79. PubMed ID: 20146864
[TBL] [Abstract][Full Text] [Related]
8. Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension?
Weber M
J Hypertens Suppl; 2009 Jul; 27(5):S9-14. PubMed ID: 19587555
[TBL] [Abstract][Full Text] [Related]
9. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).
Cowan BR; Young AA; Anderson C; Doughty RN; Krittayaphong R; Lonn E; Marwick TH; Reid CM; Sanderson JE; Schmieder RE; Teo K; Wadham AK; Worthley SG; Yu CM; Yusuf S; Jennings GL;
Am J Cardiol; 2009 Dec; 104(11):1484-9. PubMed ID: 19932779
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical and clinical experience of telmisartan in cardiac remodelling.
Verdecchia P
J Int Med Res; 2005; 33 Suppl 1():12A-20A. PubMed ID: 16222896
[TBL] [Abstract][Full Text] [Related]
11. Renin-angiotensin system blockade and cardiovascular and renal protection.
Hoogwerf BJ
Am J Cardiol; 2010 Jan; 105(1 Suppl):30A-5A. PubMed ID: 20102971
[TBL] [Abstract][Full Text] [Related]
12. New treatment strategies for patients with hypertension and insulin resistance.
Kurtz TW
Am J Med; 2006 May; 119(5 Suppl 1):S24-30. PubMed ID: 16563944
[TBL] [Abstract][Full Text] [Related]
13. Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme.
Zimmermann M; Unger T
Expert Opin Pharmacother; 2004 May; 5(5):1201-8. PubMed ID: 15155118
[TBL] [Abstract][Full Text] [Related]
14. Microalbuminuria and hypertension in HIV-infected patients: a preliminary study of telmisartan.
Ucciferri C; Falasca K; Mancino P; Di Iorio A; Vecchiet J
Eur Rev Med Pharmacol Sci; 2012 Apr; 16(4):491-8. PubMed ID: 22696876
[TBL] [Abstract][Full Text] [Related]
15. Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats.
Kobayashi N; Ohno T; Yoshida K; Fukushima H; Mamada Y; Nomura M; Hirata H; Machida Y; Shinoda M; Suzuki N; Matsuoka H
Am J Hypertens; 2008 May; 21(5):576-81. PubMed ID: 18437150
[TBL] [Abstract][Full Text] [Related]
16. Rationale for double renin-angiotensin-aldosterone system blockade.
Unger T; Stoppelhaar M
Am J Cardiol; 2007 Aug; 100(3A):25J-31J. PubMed ID: 17666194
[TBL] [Abstract][Full Text] [Related]
17. Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease studies.
Verdecchia P; Dagenais G; Healey J; Gao P; Dans AL; Chazova I; Binbrek AS; Iacobellis G; Ferreira R; Holwerda N; Karatzas N; Keltai M; Mancia G; Sleight P; Teo K; Yusuf S;
J Hypertens; 2012 May; 30(5):1004-14. PubMed ID: 22495138
[TBL] [Abstract][Full Text] [Related]
18. Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?
Neldam S
Future Cardiol; 2010 Jan; 6(1):129-35. PubMed ID: 20014992
[TBL] [Abstract][Full Text] [Related]
19. A review of telmisartan in the treatment of hypertension: blood pressure control in the early morning hours.
Gosse P
Vasc Health Risk Manag; 2006; 2(3):195-201. PubMed ID: 17326326
[TBL] [Abstract][Full Text] [Related]
20. Beyond the classic angiotensin-receptor-blocker profile.
Kurtz TW
Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S19-26. PubMed ID: 18580862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
